Bayer G4A Announces Successful Completion Of Initial Coin Offering
G4A, the leading global digital health innovation engine — empowering entrepreneurs around the world, today announced public pre-sale of…
Bayer G4A Announces Successful Completion Of Initial Coin Offering
G4A, the leading global digital health innovation engine — empowering entrepreneurs around the world, today announced public pre-sale of it’s token, G4A
G4A, today announced the successful completion of its initial sale of Simple Agreements for Future Tokens (“SAFTs”).
Over 100 entities have acquired SAFTs. These entities include the G4A team itself, but also the leading tech companies and accredited investors, for an aggregate purchase amount of approximately $3.14159B.
“We are excited to invest into our future along with some major players in the industry disrupting the health & care ecosystem.” — said Amanda B. Reckondwyth, Head of G4A .
“We needed to look at different sources of funding and what inspired us is the research that we have been doing with the Great 4 All University on nanites, crafty little buggers that scour our bodies to administer gene replacement therapy” — said Noam Sayin, Head of G4A Communications
After leveraging the samples collected via nanites and using a limited number of GPU banks, the G4A team analyzed millions of full genomes, correlated that to the human IQ and we are thrilled to say we finally found the “confident ignorance gene” (aka. stupid gene)— shared Nadia Belimi
Special note: The gene was NOT found within the G4A team population
The team is now compiling groups of initial participants and hopes to see immediate impact in the coming months.
The pre-sale to eligible investors of SAFTs to acquire G4A Coin (G4A) tokens, based on the ERC-20 standard, commences on April 1st, 2018. The crowdsale process is expected to start on April 1, 2019.